Last reviewed · How we verify

NCT03313648

A Study of Laparoscopic Hepatectomy Versus RFA in the Treatment of Recurrent HCC

Status unknown NA Last updated 18 October 2017
What this trial tests

NA trial testing Laparoscopic Hepatectomy in Hepatocellular Carcinoma Recurrent in 180 participants. Status unknown.

Timeline
1 September 2016
Primary endpoint
1 September 2021
1 September 2021

Quick facts

Lead sponsorSouthwest Hospital, China
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment180
Start date1 September 2016
Primary completion1 September 2021
Estimated completion1 September 2021
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Southwest Hospital, China

Who can join

Adults 18 to 70, any sex, with Hepatocellular Carcinoma Recurrent. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To observe and compare the short-term and long-term oncological outcome of laparoscopic hepatectomy and radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma .

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Laparoscopic Hepatectomy

Trials testing the same drug.

Other recruiting trials for Hepatocellular Carcinoma Recurrent

Currently open trials in the same condition.

Other Southwest Hospital, China trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03313648.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing